GlassScriptPhysician profile
Jennifer Tenhover
NPI 1659422608
$41,510.40
in general payments reported to CMS, 2019-2025
13 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $5,343 · 2023: $16K · 2024: $467 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $11K · Honoraria: $3,300 · Food and Beverage: $2,305 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,166.25 |
| Travel and Lodging | $10,783.44 |
| Honoraria | $3,300.00 |
| Food and Beverage | $2,304.64 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $375.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27,214.71 | 2023-2025 | Imdelltra (Amg757), Lumakras |
| G1 Therapeutics, INC. | $8,207.54 | 2022-2023 | Cosela |
| Pharmacosmos Therapeutics INC. | $3,642.60 | 2024-2025 | Cosela |
| Glaxosmithkline, LLC. | $640.00 | 2022 | |
| Daiichi Sankyo INC. | $372.38 | 2024-2025 | Datroway, Enhertu |
| Galvanize Therapeutics, INC | $347.52 | 2023-2024 | Aliya System |
| Takeda Pharmaceuticals U.S.A., INC. | $243.82 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $237.91 | 2021 | |
| Jazz Pharmaceuticals INC. | $225.63 | 2023 | |
| Genzyme Corporation | $118.80 | 2022 | |
| Genentech USA, INC. | $111.44 | 2022 | |
| Merck Sharp & Dohme LLC | $86.32 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $61.73 | 2024 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Tenhover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.